BLAB — Britannia Life Sciences Income Statement
0.000.00%
Last trade - 00:00
- CA$9.74m
- CA$19.28m
- CA$6.40m
- 40
- 85
- 14
- 43
2018 November 30th | 2019 November 30th | 2020 November 30th | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.186 | 0.974 | 0.032 | 7.3 | 6.4 |
Cost of Revenue | |||||
Gross Profit | 0.137 | 0.338 | 0.02 | 5.26 | 4.64 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 11.6 | 6.39 | 1.66 | 16.9 | 4.84 |
Operating Profit | -11.4 | -5.41 | -1.62 | -9.59 | 1.56 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -11.9 | -7.13 | -3.2 | -13.3 | 5.86 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11.9 | -7.13 | -3.2 | -14 | 5.84 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -11.9 | -7.13 | -3.2 | -15.5 | 5.08 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.9 | -7.13 | -3.2 | -15.5 | 5.08 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.15 | -1.19 | -0.439 | -0.082 | 0.023 |